Neuphoria Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $1,174 | $0 | $0 | $0 |
Gross Profit | 1,174 | 0 | 0 | 0 |
EBITDA | -5,360 | -1,045 | -3,895 | -5,486 |
EBIT | -5,525 | -1,211 | -4,060 | -5,652 |
Net Income | -4,904 | -505 | 1,864 | -9,906 |
Net Change In Cash | 1,174 | 0 | 0 | 0 |
Free Cash Flow | 1,213 | -3,336 | -6,435 | -3,794 |
Cash | 19,865 | 19,440 | 22,170 | 13,649 |
Basic Shares | 5,411 | 5,411 | 4,536 | 2,246 |
Annual Financials
| Values in thousands | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
Revenue | $1,174 | $15,649 | $0 | $0 |
Gross Profit | 1,174 | 15,649 | -662 | -671 |
EBITDA | -15,788 | -466 | -25,981 | -31,479 |
EBIT | -16,451 | -1,129 | -26,644 | -32,450 |
Net Income | -13,451 | -369 | -15,492 | -32,181 |
Net Change In Cash | 1,174 | 15,649 | 0 | 0 |
Free Cash Flow | -12,353 | 77 | -14,681 | -9,846 |
Cash | 19,865 | 14,210 | 12,608 | 8,056 |
Basic Shares | 4,396 | 1,978 | 149,800 | 122,394 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.13 |
2026-03-31 | -$0.09 |
2025-12-31 | $0.41 |
2025-09-30 | -$4.41 |